Clinical trials: BRONCHIAL ASTHMA
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.
- Trial name
- CS201 (NCT02217332)
- Testing
- dexpramipexole
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Knopp Biosciences
Asthma; Allergic Rhinitis
Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers
A randomized, single-center, double-blind, ascending multiple-dose, placebo-controlled study to evaluate the tolerability and pharmacokinetics of CSPCHA115 capsules in Chinese healthy volunteers.
- Trial name
- NCT04161547
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Asthma
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, symptoms, and use of rescue medication in children with persistent asthma.
- Trial name
- NCT00163410
- Testing
- Ciclesonide
- Where
- 16 sites in India
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma
Safety and Efficacy of YHD001 in Asthma
The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma.
- Trial name
- NCT01424124
- Testing
- YHD001 dose level 1, YHD001 dose level 2, Singulair
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yuhan Corporation
Asthma
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in…
- Trial name
- NCT02141854
- Testing
- FS MDPI, Fp MDPI, Albuterol/salmeterol HFA MDI
- Where
- 154 sites in United States, Canada and 7 more
- Volunteers
- 882 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler
The Fluticasone Propionate/Salmeterol combination (FSC) at a dose of 100/50 micrograms (mcg) twice daily in DISKUS inhaler (also known as ACCUHALER®, Ddpi) inhaler is a recognised and licensed therapy for the treatment of asthma.
- Trial name
- NCT02218762
- Testing
- Fluticasone Propionate/Salmeterol Xinafoate DISKUS, Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS
- Sponsor
- GlaxoSmithKline
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Asthma
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety…
- Trial name
- Breztri rPMS (NCT07570394)
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health…
- Trial name
- CONNECT1 (NCT03890666)
- Testing
- Albuterol eMDPI DS, albuterol
- Where
- 29 sites in United States
- Volunteers
- 333 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Asthma, Rhinitis Allergic
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
Allow physicians not familiar with anti-leukotriene based therapy to test it
- Trial name
- NCT00380705
- Testing
- MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 91 people
- Sponsor
- Organon and Co
Asthma
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma.
- Trial name
- NCT00556673
- Testing
- indacaterol maleate/mometasone furoate, fluticasone proprionate / salmeterol xinafoate
- Where
- 2 sites in France, Germany
- Volunteers
- 31 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma
The purpose of this study is to evaluate the efficacy and safety of Flamboyant 200/12 association in adults with asthma.
- Trial name
- NCT04191447
- Testing
- Flamboyant 200/12, Budesonide / Formoterol 400/12
- Where
- Brazil
- Volunteers
- 134 people
- Sponsor
- EMS
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Asthma
Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma
The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects…
- Trial name
- NCT00064389
- Testing
- levalbuterol tartrate HFA MDI, racemic albuterol
- Where
- 96 sites in United States, Canada
- Volunteers
- 746 people
- Sponsor
- Sumitomo Pharma America, Inc.
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.